Epstein-Barr Viral Infections - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epstein-Barr Viral Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Epstein-Barr Viral Infections - Pipeline Review, H1 2015', provides an overview of the Epstein-Barr Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epstein-Barr Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epstein-Barr Viral Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Epstein-Barr Viral Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Epstein-Barr Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epstein-Barr Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Epstein-Barr Viral Infections Overview 7
Therapeutics Development 8
Pipeline Products for Epstein-Barr Viral Infections - Overview 8
Pipeline Products for Epstein-Barr Viral Infections - Comparative Analysis 9
Epstein-Barr Viral Infections - Therapeutics under Development by Companies 10
Epstein-Barr Viral Infections - Therapeutics under Investigation by Universities/Institutes 11
Epstein-Barr Viral Infections - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Epstein-Barr Viral Infections - Products under Development by Companies 15
Epstein-Barr Viral Infections - Products under Investigation by Universities/Institutes 16
Epstein-Barr Viral Infections - Companies Involved in Therapeutics Development 17
Cell Medica Limited 17
Epiphany Biosciences, Inc. 18
Theravectys S.A. 19
ViroStatics, srl 20
Epstein-Barr Viral Infections - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cell Therapy for Infectious Disease - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cell Therapy for Infectious Diseases - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CMD-003 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
EBV vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EBV vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Peptide for EBV Infections - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit CDK9 for EBV and HSV Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecules for EBV Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules for Viral Infections - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecules to Inhibit EBNA1 for EBV Latent Infection - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Vaccine for EBV Associated Nasopharyngeal Cancer - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
valomaciclovir stearate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Epstein-Barr Viral Infections - Recent Pipeline Updates 51
Epstein-Barr Viral Infections - Dormant Projects 52
Epstein-Barr Viral Infections - Product Development Milestones 53
Featured News & Press Releases 53
Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus 53
Nov 08, 2011: Protection against Epstein-Barr virus: new approach towards an effective vaccine 54
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 55
Disclaimer 56

List of Tables
Number of Products under Development for Epstein-Barr Viral Infections, H1 2015 8
Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Epstein-Barr Viral Infections - Pipeline by Cell Medica Limited, H1 2015 17
Epstein-Barr Viral Infections - Pipeline by Epiphany Biosciences, Inc., H1 2015 18
Epstein-Barr Viral Infections - Pipeline by Theravectys S.A., H1 2015 19
Epstein-Barr Viral Infections - Pipeline by ViroStatics, srl, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Stage and Target, H1 2015 23
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Epstein-Barr Viral Infections Therapeutics - Recent Pipeline Updates, H1 2015 51
Epstein-Barr Viral Infections - Dormant Projects, H1 2015 52